All Posts Tagged With: "COV"
(CRDC) Cardica Reaches Second Milestone for Their Microcutter
Surgical devices maker Cardica (CRDC) has achieved the second milestone for its Microcutter product line under its distribution pact with Century Medical, a leading supplier of medical equipment in Japan....
(CRDC) Cardica Reports Progress For Microcutter XPRESS Surgical Cutting and Stapling Device
Surgical devices maker Cardica Inc (CRDC) has reportedly completed the key internal design verification process necessary for applying the European CE Mark to its Microcutter XPRESS 30 surgical cutting and...
(COV) Covidien’s Pipeline Device Cleared
Leading healthcare products maker Covidien plc (COV) has secured Premarket Approval (“PMA”) from the U.S. Food and Drug Administration’s (“FDA”) for its Pipeline Embolization Device for treating...
(JNJ) Japan Quake Impact on Medical Technology
Tremors triggering a quake, which struck about 250 miles north of Tokyo, followed by a colossal Tsunami, wreaked havoc on the people of the “Land of the Rising Sun” on March 11, resulting in massive carnage and destruction.
The catastrophe,...
(BXP) Company News for January 27, 2011 – Corporate Summary
• Qualcomm (NASDAQ:QCOM) reported Q1 EPS of $0.82, ex-items, ahead of the Zacks Consensus Estimate of $0.63 per share. Revenues for the quarter rose 25% year-over-year to $3.35 billion, above the Zacks Consensus Estimate...
(LGF) Activist Investors Are Ready to Fight in 2011
by Marc Lichtenfeld, Investment U’s Senior Analyst
Wednesday,...
(COV) Covidien plc Quarterly Earnings Top Expectations – Profits Skyrocket
Ireland-based health care product maker Covidien plc (COV) reported fourth-quarter fiscal 2010 (ended September 24) adjusted earnings per share of 84 cents, exceeding the Zacks Consensus Estimate of 74 cents...
(AKS) Company News for November 9, 2010 – Corporate Summary
• Chevron (NYSE:CVX) announced plans to buy Atlas Energy (NASDAQ:ATLS) for $4.3 billion, or $43.35 per share
• Bank of America (NYSE:BAC) and PNC (NYSE:PNC) sold $8.3 billion of BlackRock (NYSE:BLK) shares in a secondary offering priced at $163 per share, a 3.6%...
(COV) Covidien Raises Quarterly Dividend by 11%
Covidien plc (COV), a leading healthcare products maker, recently enhanced shareholder returns by raising its quarterly dividend by 11% to 20 cents a share from 18 cents. The revised quarterly...
(COV) Covidien Beats The Street by a Nickel
Ireland-based healthcare product maker Covidien plc (COV) reported third-quarter fiscal 2010 results with adjusted (excluding one-time items such as restructuring charges and tax-related adjustments) earnings...
(JNJ) Johnson & Johnson Announces They Will Aquire Micrus Endovascular
Johnson & Johnson (JNJ) recently announced plans to acquire medical devices maker Micrus Endovascular Corp. (MEND), based in San Jose,...
(MASI) Masimo Corporation in Expansion Mode
Masimo Corp. (MASI) recently announced the expansion of its corporate campus in Irvine, California with the addition of an adjacent 32,000 sq. ft. building. This is the company’s third building on...
(COV) Covidien Limited – Earnings Surprise Streak Broken
Covidien Limited (COV) has surprised on estimates 3 out of the last 4 quarters. The company also recently raised its dividend. Covidien is trading at 13.6x forward earnings.
Company Description
Covidien manufactures medical devices,...
(BAX) Top Health Equity Funds – Mutual Fund Commentary
Today we are featuring top-performing “Health” equity mutual funds, which primarily invest in equity securities of healthcare and related companies.
Investors can find such funds by checking out the entire list of the vitalstocks | 0 comments | Continued
(COV) Covidien Limited – Value – Zacks Rank Buy
Covidien Limited (COV), the medical device manufacturer, has surprised on estimates 7 quarters in a row. Will it do it again on Apr 30? Second quarter estimates have risen by nearly 17% in the last 3 months. COV has a forward P/E of 11.35.
Company...
(COV) – Covidien – Sales were up 14% from last year
Covidien Ltd. (COV) has been driving its revenue higher from robust sales in its international markets, which all recorded double-digit sales growth in the most recently reported quarterly results. The next-year estimate is bullish, and the company’s stock price is in...